We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+45.97%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.07B
AUM Growth
+$1.91B
Cap. Flow
+$58.2M
Cap. Flow %
0.82%
Top 10 Hldgs %
40.22%
Holding
232
New
17
Increased
84
Reduced
52
Closed
24

Top Buys

Rank Stock Value
1
GBIO
Generation Bio
GBIO
+$32.1M
2
SYK icon
Stryker
SYK
+$27.9M
3
PODD icon
Insulet
PODD
+$24.7M
4
BMY icon
Bristol-Myers Squibb
BMY
+$24.3M
5
DVA icon
DaVita
DVA
+$23.4M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$78.8M
2
ISRG icon
Intuitive Surgical
ISRG
+$34.5M
3
ILMN icon
Illumina
ILMN
+$34.1M
4
MRNA icon
Moderna
MRNA
+$33.1M
5
AKCA
Akcea Therapeutics Inc
AKCA
+$26.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.05%
2 Industrials 0.58%
3 Technology 0.42%
4 Communication Services 0.29%
5 Financials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCI icon
201
Service Corp International
SCI
$11.4B
$331K ﹤0.01%
8,500
– –
SBUX icon
202
Starbucks
SBUX
$118B
$319K ﹤0.01%
4,334
– –
BKNG icon
203
Booking.com
BKNG
$138B
$318K ﹤0.01%
5,000
– –
AZPN
204
DELISTED
ASPEN TECHNOLOGY INC
AZPN
$311K ﹤0.01%
3,000
– –
LYV icon
205
Live Nation Entertainment
LYV
$41.2B
$275K ﹤0.01%
6,200
– –
BLKB icon
206
Blackbaud
BLKB
$1.5B
$234K ﹤0.01%
4,107
– –
KOS icon
207
Kosmos Energy
KOS
$1.56B
$100K ﹤0.01%
60,000
– –
CVET
208
DELISTED
Covetrus, Inc. Common Stock
CVET
$27K ﹤0.01%
1,520
– –
APLS
209
DELISTED
Apellis Pharmaceuticals
APLS
– –
-29,900
Closed -$801K
BIIB icon
210
CALL
Biogen
BIIB
$29.9B
– –
-160
Closed -$7K
BIIB icon
211
Biogen
BIIB
$29.9B
– –
-8,500
Closed -$2.69M
BLUE
212
DELISTED
bluebird bio
BLUE
– –
-1,529
Closed -$910K
CL icon
213
Colgate-Palmolive
CL
$72.6B
– –
-6,100
Closed -$405K
KYNB
214
Kyntra Bio
KYNB
$28.5M
– –
-1,504
Closed -$1.31M
KURA icon
215
Kura Oncology
KURA
$922M
– –
-57,100
Closed -$568K
LABU icon
216
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$571M
– –
-750
Closed -$338K
MTB icon
217
M&T Bank
MTB
$36.2B
– –
-3,000
Closed -$310K
PANW icon
218
Palo Alto Networks
PANW
$264B
– –
-102,000
Closed -$2.79M
PFE icon
219
Pfizer
PFE
$140B
– –
-94,860
Closed -$2.94M
PRGO icon
220
Perrigo
PRGO
$1.4B
– –
-20,400
Closed -$981K
QDEL icon
221
QuidelOrtho
QDEL
$1.09B
– –
-113,955
Closed -$11.1M
QGEN icon
222
Qiagen
QGEN
$8.53B
– –
-87,327
Closed -$3.85M
RGEN icon
223
Repligen
RGEN
$7.44B
– –
-13,600
Closed -$1.31M
SUPN icon
224
Supernus Pharmaceuticals
SUPN
$2.68B
– –
-552,800
Closed -$9.95M
TEVA icon
225
Teva Pharmaceuticals
TEVA
$35.9B
– –
-303,000
Closed -$2.72M
6 7 8
9
10

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q2 2020 Portfolio in Review

As of Q2 2020, Bellevue Group held 232 positions worth $7.07B, up 37% from $5.16B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group's Q2 2020 filing shows 17 new, 84 increased, 52 reduced and 24 closed positions. Its largest new stake was Generation Bio: 144,000 shares worth $30.2M. The largest sale was Vertex Pharmaceuticals, an estimated $78.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q2 2020 buy was Generation Bio: 144,000 shares worth $30.2M.
  • Bellevue Group added most to Stryker in Q2 2020, an estimated $27.9M increase.
  • Bellevue Group's biggest Q2 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $78.8M.
  • Bellevue Group fully exited QuidelOrtho in Q2 2020, selling an estimated $11.1M.
  • Bellevue Group's ten largest holdings make up 40% of its $7.07B portfolio in Q2 2020.
  • Bellevue Group opened 17 new positions and closed 24 in Q2 2020.
  • Bellevue Group's portfolio value rose 37% quarter-over-quarter to $7.07B.

Based on Bellevue Group's 13F filing for Q2 2020, filed 13 Aug 2020.